{
    "nctId": "NCT03756064",
    "briefTitle": "Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer",
    "officialTitle": "Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer: a Single-arm, Ahead, Open-label Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Neoplasm, Breast, Breast Diseases",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "pCR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. female patients, 18 years \u2264 age \u2264 80 years\uff1b\n2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1\n3. Histologically confirmed invasive breast cancer\uff08early stage or locally advanced\uff09\n4. HER2 positive (HER2+++ by IHC or FISH+)\n5. Known hormone receptor status.\n6. Cardiovascular: Baseline left ventricular ejection fraction (LVEF)\u226555% measured by ECHO\n7. Signed informed consent form (ICF)\n\nExclusion Criteria:\n\n1. Metastatic disease (Stage IV) or inflammatory breast cancer\n2. Previous or current history of malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of the skin, Carcinoma in situ of the cervix.\n3. Clinically relevant cardiovascular disease: Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension \u2265180/110);\n4. Unable or unwilling to swallow tablets.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}